Search
forLearn
5 / 801 resultslearn Cepharanthine
learn capilia longa
learn Cacao Seed
learn platycladus orientalis
Research
5 / 1000+ resultsresearch Cosmos caudatus Kunth. Leaf Extract Herbal Nanosuspension Formulations, Characterization, and Cytotoxicity Approach Against MCF-7 Breast Cancer Cells
Kenikir leaf extract nanosuspension may help inhibit breast cancer cell growth.
research Modulation of AR-FGF-2-TGF beta Axis by Cosmos caudatus Suppresses Prostatic Epithelial Proliferation in a BPH Rat Model: A Comparative Study with Finasteride
Cosmos caudatus extract is as effective as finasteride for treating benign prostatic hyperplasia without its side effects.
research A review on traditional uses, phytochemistry and pharmacology of Eclipta prostrata (L.) L.
Eclipta prostrata has many traditional uses and health benefits, but more research is needed to understand how it works and ensure it's safe.
research Cosmetic potential of Southeast Asian herbs: an overview
Southeast Asian herbs show promise for skin and hair care, but more research is needed to confirm their effectiveness in cosmetics.
research Senotherapeutic Potential of Araliadiol in Senescent Human Dermal Fibroblasts: An In Vitro Study Using Three Senescence Models
Araliadiol may help reduce skin aging and inflammation without killing cells.
Community Join
5 / 1000+ resultscommunity Cosmo Pharma 2025 Investor Day Report
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
community What’s your views on clascoterone 5% topical solution by cosmo
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.
community Breezula Phase III 12-Month Data Released by Cosmo Pharma
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.